Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pediatric Pharm Exam 3 > Diabetes Mellitus > Flashcards

Diabetes Mellitus Flashcards

1
Q

Epidemiology (6)

A
  1. 18 million individuals diagnosed in the US

High risk groups

  1. African Americans
  2. Hispanics
  3. American Indians
  4. Asian Americans

Complications
6. Leading cause of blindness, end-stage renal disease, amputations, and infection; will be cumulative with duration of uncontrolled blood sugar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fasting Plasma Glucose (FPG)

A

No caloric intake for at least 8 hourss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oral Glucose Tolerance Test (OGTT)

A

Administration of glucose containing:
75 grams anhydrous glucose
1.75 g/kg of body weight to a maximum of 75 grams

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Impaired Glucose Tolerance (IGT) (2)

A
  1. Measure of carbohydrate intolerance 2 hours following OGTT
  2. Also known as ‘Pre Diabetes’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Impaired Fasting Glucose (IFG)

A

Measure of disturbed carbohydrate metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Classification

Type 1 Diabetes (T1DM) (3)

A
  1. Autoimmune destruction of B cells of the pancreas
  2. Onset usually preschool to teenage (can see neonatal diabetes)
  3. Antibody formation:
    - Islet cells
    - Glutamic acid decarboxylase
    - Insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Classification Type 2 Diabetes (T2DM) (2)

A
  1. Insulin resistance and a relative lack of insulin secretion
  2. Metabolic Syndrome
    - Hypertension
    - Dyslipidemia
    - Elevated plasminogen activator-1 inhibitors (PAI-1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Miscellaneous Causes (6)

A
  • Pancreatitis
  • Cystic Fibrosis (CF-Related Diabetes)
  • Cushing syndrome or medication induced
  • Hyperthyroidism
  • Infections (Congenital rubella or cytomegalovirus)
  • Monogenic (Neonatal diabetes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q 
Associated with genetic syndromes (2)
Other syndrome (1)
A

Associated with some genetic syndromes

  1. Down’s syndrome
  2. Prader-Willi syndrome

Other: Gestational diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Screening by American Diabetes Association (5)

A
  1. Overweight (BMI > 85% percentile)

With at least two of the following:

  1. Family history
  2. Race (Native Americans, African Americans, Hispanic Americans, Asians/South Pacific Islanders)
  3. Signs of insulin resistance
  4. Screen every 2 years starting at 10 years of age or onset of puberty
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Signs and Symptoms of DM (6)

A
  1. Polyuria, Polydipsia, Polyphagia
  2. Blurred vision
  3. Weight loss
  4. Fatigue
  5. DKA
  6. Slow healing wounds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Neuropathies (Microvascular) Diabetic (2)

A
  1. Sorbitol accumulation

2. Protein glycosylation (thickened basement membrane)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Neuropathies (Microvascular) Peripheral (2)

A
  1. Parathesia and pain

2. Begins in distal extremeties but progresses proximally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Neuropathies (Microvascular) Autonomic (6)

A
  1. Impotence
  2. Gastroparesis
  3. Diarrhea
  4. Neurogenic bladder
  5. Orthostatis
  6. Diminished response to hypoglycemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Neuropathies (Microvascular) Retinopathy (6)

A
  1. Leading cause of new blindness

Retinal changes

  1. Microaneurysms
  2. Increased permeability
  3. Occlusion
  4. Proliferation of new blood vessels
  5. Cancers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nephropathy (microvascular) (5)

A
  1. 30-40% of all diabetic patients may develop
  2. Proteinuria
  3. Decreased GFR
  4. Increased arterial blood pressure
  5. Microalbuminuria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Dyslipidemia (macrovascular) (4)

A
  1. Increased risk of coronary artery disease
  2. Goal LDL < 100 mg/dL
  3. Dietary intervention needed
  4. Statins should be considered; Age > 8 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Hypertension (macrovascular) (4)

A
  1. Goal BP determined by age, gender, height
  2. Lifestyle modifications
  3. ACE Inhibitors drug of choice
  4. Renal protective effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Treatment Goals for Age < 6 years
FBG
Bedtime
HbA1C

A

Age < 6 years

FBG – 100-180

Bedtime – 110-200

HbA1C –7.5-8.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Treatment Goals for Age 6-12 years
FBG
Bedtime
HbA1C

A

Age 6-12 years

FBG 90-180

Bedtime 100-180

HbA1C <8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Treatment Goals for Age 13-19 years
FBG
Bedtime
HbA1C

A

Age 13-19 years

FBG 90-130

Bedtime 90-150

HbA1C <7.5%

22
Q

Goals for therapy (5)

A
  1. Weight loss or maintain appropriate weight & growth (good diet)
  2. Increase in exercise capacity
  3. Normalization of glycemia
  4. Control of comorbidities
  5. Education is HUGE!!!
23
Q

Pharmacologic Treatment for DM Type 1

24
Q

Pharmacologic Treatment for DM Type 2 (6)

A
  • Insulin
  • Biguanides
  • Sulfonylureas
  • Meglitinides
  • Alpha Glucosidase Inhibitors
  • Thiazolidinediones
  • … and more
25
Q

Endogenous Insulin (6)

A
  1. Normal Activity
  2. Increases glucose uptake in tissues
  3. Increases liver glycogen
  4. Decreases glycogenolysis
  5. Increases fatty acid synthesis
  6. Decreases fatty acid metabolism
26
Q

Exogenous Insulin (2) Types (4)

A
  1. Similar pharmacologic activity as endogenous chemical
  2. Different types depend on structure changes Pharmacokinetic properties differentiates different types of insulin

Types:

  1. Rapid-acting
  2. Short-acting
  3. Intermediate-acting
  4. Long-acting
27
Q

Rapid Acting Insulin - 3 Types

A
  1. Insulin Aspart (NovoLog)
  2. Insulin Lispro (Humalog)
  3. Insulin Glulisine (Apidra)
28
Q

Rapid Acting Insulin PK Parameters: Onset, Peak, Duration

A
  • Onset: 15 min
  • Peak: 1 – 2 hrs
  • Duration: 3 – 4 hrs
29
Q

Rapid Acting Insulin: Available dosage forms (4)

A

Insulin vials
Insulin pens
- Prefilled
- Re-usable

30
Q

Short-Acting Insulin: Available products

A

Insulin Regular (novolin R, Humalin R)

31
Q

Short-Acting Insulin PK Parameters: Onset, peak, duration

A

Onset: 30-60min
Peak: 2 - 4 hrs
Duration: 4-8 hrs

32
Q

Short-Acting Insulin: Available dosage forms (1)

A

Insulin Vials

33
Q

Intermediate Acting Insulin: Available Products

A

Insulin NPH (Novolin N)

34
Q

Intermediate Acting Insulin PK Parameters: Onset, Peak, duration

A
  • Onset: 1-2 hrs
  • Peak: 4-10 hrs
  • Duration: 10-18 hrs
35
Q

Intermediate Acting Insulin: Available dosage form

A

Insulin vials

36
Q

Combo Products (2)

A
  1. NovoLIN® 70/30

2. HumaLOG® 70/30

37
Q

Long Acting Insulin: available agents

A

Insulin Determir (Levemir)

38
Q

Long Acting Insulin: onset, peak, duration

A

Onset: 6 hrs
Peak: 12 – 16 hrs
Duration: 2hrs

39
Q

Long Acting Insulin Dose Frequency

A

q12 – q24

40
Q

Long Acting Insulin, Approved for?

A

use in pregnancy

41
Q

Insulin Glargine: onset, peak, duration

A

Onset: 4 – 5 hrs
No peak
Duration: 22 – 24hrs

42
Q

Insulin Glargine Dose frequency

A

Dose freq: q24 (q12)

43
Q

Insulin Glargine Available dosage forms (2)

A
  1. 100 Units/mL

2. Toujeo® 200 Unit/mL

44
Q 
Insulin Pearls (2)
Available in...
A

Most insulin available in U-100

100 units of insulin per mL

45
Q

Combination preparations available (2)

A
  1. Pre-mixed insulin analogs
    - 72/25 (75% NPL, 25% lispro)
    - 70/30 (70% APS, 30% aspart)
  2. NPH-regular combinations
    - 70/30 (70% NPH, 30% regular)
46
Q

Dose Regimen Basal + Bolus (4)

A
  1. Long-acting insulin should be 40-60% of total daily insulin requirement
  2. Regular or rapid acting is the remainder
  3. Regular insulin 20-30 minutes prior to eating
  4. Intermediate or long-acting at bedtime or twice daily
47
Q

Dose Regimen (2)

A
  1. Continuous SC infusion – Insulin pump

2. Twice daily injections with NPH

48
Q

ADE Insulin (5)

A
  1. Hypoglycemia
  2. Weight gain
  3. Lipodystrophy
  4. Lipohypertrophy
  5. Lipoatrophy
49
Q

Insulin Techniques (6)

A
  1. Rotate injection sites; Abdomen, thigh, buttocks, lateral aspect of arm
  2. Clean before/after injection
  3. Examine bottle, roll gently to warm
  4. Inject air and draw up desired dose
  5. Pinch skin with one hand
  6. Pull plunger back to look for blood
50
Q

Insulin Pearls (4)

A
  1. Intravenous administration
    - Regular insulin ONLY
    - Used in crisis management; DKA, Surgical procedures
  2. Adjust basal insulin dose 1-2 units at a time
  3. Every unit of insulin may decrease glucose by 25-50 units
  4. High blood sugar at office visits
    - Sick days
51
Q

Somogyi Effect (2)

A
  1. Post-hypoglycemic hyperglycemia

2. Decrease bedtime NPH or give evening NPH later

52
Q

Dawn Phenomenon (2)

A
  1. Rise in glucose in early morning hours

2. Increase evening NPH dose

Pediatric Pharm Exam 3 (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions